Search

Objectives: Palonosetron is a novel 5-hydroxytryptamine (5 HT) receptor antagonist, which has been shown to be superior to first generation 5 HT receptor antagonists regarding the prevention of acute, delayed and overall chemotherapy-induced nausea and vomiting. First generation 5 HT receptor antagonists may induce electrocardiographic changes of heart rate and repolarization. The acute cardiac effect of palonosteron is unknown. The purpose of this study is to determine acute effects of palonosetron on electrocardiographic (ECG) parameters in cancer patients. Materials and methods: The study had a prospective design. Seventy-six cancer patients with normal cardiac function who received palonosetron for prevention of chemotherapy-induced nausea and vomiting were enrolled. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated. Results: Median heart rate did not differ among 76 patients enrolled before and after palonosetron administration ( p: 0.6). Systolic and diastolic blood pressures were not significantly different before and after palonosteron ( p values 0.9 and 0.3, respectively). Although median QT min value was higher after palonosetron administration than before palonosetron administration, the difference was not statistically significant ( p: 0.6). Conclusion: Palonosetron seems to have no acute arrhythmogenic potential. [ABSTRACT FROM AUTHOR]

Stereotactic body radiotherapy (SBRT) is increasingly being used to treat oligometastatic cancers, but high-level evidence to support policy decisions is lacking in patients with colorectal carcinoma (CRC). The purpose of this study was to determine the prognostic factors for survival in oligometastatic colorectal cancer patients treated with SBRT in a multicentric setting. The clinical data of 437 oligometastatic CRC patients who received metastasis directed treatment (MDT) via SBRT at 18 institutions between February 2007 and February 2021 were reviewed retrospectively. Patients either had de novo oligometastasis (≤5 metastases) at the time of diagnosis or had oligometastatic recurrences during follow-up. All patients were treated with the goal of curing their metastasis, and 839 lesions were irradiated. The average age was 61 years (range; 27-92 years). The majority of patients (58.8%) had colon carcinoma with a single organ metastasis (88.8 %). The average number of metastatic lesions was 2 (range, 1-5). There were 103 patients with liver metastasis, 222 patients with lung metastasis, 58 patients with lymph node metastasis, 60 patients with bone metastasis, 32 patients with brain metastasis, and 6 patients with other organ metastasis. Before RT, the median CEA and Ca-19-9 levels were 5.16 ng/mL (range: 0-8181.1 ng/mL) and 19.4 (range: 0.60 - 3693), respectively. After RT, the median CEA and Ca-19-9 were 5.00 ng/mL (range, 0.4-5693v ng/mL) and 18 (range, 0 - 6577), respectively. The average period of follow-up was 15.2 months (range, 0.3-91.5 months). The rates of OS and PFS after two years were 76.3 % and 28.1 %, respectively. Age (p<0.001), pre-RT CEA (p=0.006), pre-RT Ca19-9 (p=0.02), post-RT CEA (p=0.01), and post-RT Ca19-9 (p=0.02) were all significant prognostic factors for OS in univariate analysis. Age (HR=1.03, 95 % CI, 1.01-1.04, p=0.004) and pre-RT CEA (HR=1.01, 95 % CI, 1.00-1.02, p=0.04) were independent predictors of OS in multivariate analysis, while post-RT CEA (HR=1.93, 95 % CI, 1.28-2.90, p=0.002) was an independent predictor of PFS. SBRT to oligometastatic lesions was found to be a safe and effective treatment modality for patients with colorectal cancer. Survival was predicted by age, baseline CEA, and the Ca19-9 response to MDT. Additional prospective studies with larger cohorts are necessary to validate our findings. [ABSTRACT FROM AUTHOR]